Associations - Jemperli (dostarlimab-gxly)

MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-L/dMMR	Small Intestinal Carcinoma	MSI-L/dMMR	Small Intestinal Carcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Hepatocellular Cancer	MSI-H/dMMR	Hepatocellular Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Pancreatic Adenocarcinoma	MSI-H/dMMR	Pancreatic Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	niraparib + dostarlimab-gxly Sensitive: B - Late Trials niraparib + dostarlimab-gxly Sensitive : B	niraparib + dostarlimab-gxly Sensitive: B - Late Trials niraparib + dostarlimab-gxly Sensitive : B
MSI-H/dMMR	Renal Cell Carcinoma	MSI-H/dMMR	Renal Cell Carcinoma	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1
MSI-H/dMMR	Gallbladder Cancer	MSI-H/dMMR	Gallbladder Cancer	dostarlimab-gxly Resistant: C1 - Off-label dostarlimab-gxly Resistant : C1	dostarlimab-gxly Resistant: C1 - Off-label dostarlimab-gxly Resistant : C1
MSI-H/dMMR	Breast Cancer	MSI-H/dMMR	Breast Cancer	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1
MSI-H/dMMR	Ovarian Cancer	MSI-H/dMMR	Ovarian Cancer	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1
MSI-H/dMMR	Gastrointestinal Cancer	MSI-H/dMMR	Gastrointestinal Cancer	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1	dostarlimab-gxly Sensitive: C1 - Off-label dostarlimab-gxly Sensitive : C1
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	dostarlimab-gxly Sensitive: C2 – Inclusion Criteria dostarlimab-gxly Sensitive : C2	dostarlimab-gxly Sensitive: C2 – Inclusion Criteria dostarlimab-gxly Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	dostarlimab-gxly Sensitive: C2 – Inclusion Criteria dostarlimab-gxly Sensitive : C2	dostarlimab-gxly Sensitive: C2 – Inclusion Criteria dostarlimab-gxly Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + niraparib + dostarlimab-gxly Sensitive: C3 – Early Trials bevacizumab + niraparib + dostarlimab-gxly Sensitive : C3	bevacizumab + niraparib + dostarlimab-gxly Sensitive: C3 – Early Trials bevacizumab + niraparib + dostarlimab-gxly Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + niraparib + dostarlimab-gxly Sensitive: C3 – Early Trials bevacizumab + niraparib + dostarlimab-gxly Sensitive : C3	bevacizumab + niraparib + dostarlimab-gxly Sensitive: C3 – Early Trials bevacizumab + niraparib + dostarlimab-gxly Sensitive : C3
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
TMB-H	Solid Tumor	TMB-H	Solid Tumor	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
PD-L1 overexpression	Solid Tumor	PD-L1 overexpression	Solid Tumor	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSI-H/dMMR + POLE mutation	Gastric Cancer	MSI-H/dMMR + POLE mutation	Gastric Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSI-H/dMMR + POLE mutation	Colorectal Cancer	MSI-H/dMMR + POLE mutation	Colorectal Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3

Jemperli (dostarlimab-gxly)

Associations
(43)

Associations
(43)

Jemperli (dostarlimab-gxly)

Associations(43)

Associations(43)

Associations
(43)

Associations
(43)